Scancell Share Discussion Threads

[notknowing] 04/2/2021 09:57

Is it me or is member 'Gazza' a bit of a tit? Did he get spiked at 17p or something?

[gazza] 04/2/2021 09:42

Yes, looking forward to 30/40p next week lol.

[notknowing] 04/2/2021 09:02

Are we still all feeling positive this morning?

[2tyke] 04/2/2021 08:40

Actually superg it was the IOF bb that you barred me from.
I think you thought I was being overly negative about it technically.
It did turn out to be a disaster story though.
You are better on this one SCLP.
Did you notice that the gap ob the chart was closed at 12.5p yesterday ? Accompanied by the expected strong move higher.

[emptyend] 03/2/2021 22:15

Guardian article extract......need to find areas of the virus that are conserved in mutations........."The great hope for drug treatments against COVID-19 -- the monoclonal antibodies -- is failing against variants of the virus, such as those that have emerged in South Africa and Brazil, scientists have found. There have been high expectations of the drugs. One, made by Regeneron in the United States, is being trialled in hospital patients in the UK. But to the dismay of those who work on therapies against the disease, all 3 leading contenders -- Regeneron's, and drugs from Eli Lilly and GlaxoSmithKline - fail against one or more of the variants.The antibodies have huge advantages as treatments, said Nick Cammack, who leads the COVID-19 therapeutics accelerator at Wellcome. They are derived from cloning a human white blood cell and mimic the effects of the immune system. They are very safe, specifically engineered to target the virus and their use looked highly promising in the early stage of disease to stop it progressing."The challenge came at Christmas [2020] when these new variants appeared -- the South Africa and Brazil ones particularly. The changes the virus makes in its spike proteins actually throw off these antibodies," he said. "So basically, most of the front-running antibody therapies for COVID which are the front-running therapies for COVID, I should say -- so the great hope -- are lost to the South African and Brazilian variants."GlaxoSmithKline's treatment still works against those variants, but not against the one that emerged in Kent in the UK. But with the coronavirus mutating as much as it has done already, Cammack does not expect any of the current drugs to be effective for long.Researchers now need to find "conserved" regions of the virus that do not mutate to target with antibodies. "I think it's pretty clear, whilst we've seen South Africa, UK, and Brazil variants, there will be others. And we need mass sequencing, genetic sequencing of the virus around the world, which will reveal where the changes are made and also reveal where conserved regions are," he said.The drugs still work against the original virus and are being used in Europe and the United States. The monoclonal antibodies were chosen to target the spike protein of the virus which attaches to cells in the human body. In general, he said, that region of the virus does not change much, because if it does, it won't attach so well to cells. "Well, here we are with a virus that makes a change that actually helps it stick to the cell even better. So these monoclonals are lost," said Cammack. "So we're somewhat back to square one honestly.""

[wanderer1210_0] 03/2/2021 19:18

Problem is you've not sold at £8 ?

[2tyke] 03/2/2021 18:56

That's the one superg...it's your old sparing partner pharma here.
I did try and get on VRS bb to warn you about that one, but you barred me matey...lol

[inanaco] 03/2/2021 15:58

scib2 is the same why change the format ?

scib2 + (avidimab) may make the 55% expected rise to ? the ? has value

what advantage with out Check point ? the vaccine is not designed as a stand alone against solid tumour only but as an adjuvant (surgery etc), the check point gives the vaccine the advantage against solid without it, the results would be poor

so the advantage comes from synergy ... not each one on its own

[torquayfan] 03/2/2021 15:33

Inan your 36480 - "TF they (CRUK) have never dropped the Combo and Scancell will not either." I get it - SCIB1 Combo is going ahead - but SCIB2?

Today's RNS - "Recent studies have demonstrated that Scancell's AvidiMab™ technology can be applied to an ImmunoBody® to increase the potency of the T cell response; this modification could be applied to SCIB2 to further enhance the responses induced and extend the patent protection on the product."

With SCIB2 now back 'in-house' - I wondered if SCIB2 might be able to proceed to a trial in 'Immunobody enhanced by AvidiMab' mode without the Combo with CI - there are obvious advantages.

After all, SCIB1 completed Phase 1/2 trials for melanoma with success and Immunobody in SCIB2 form, now bolstered by AvidiMab, might do very well on it's own ?

That's the point I'm discussing - it seems reasonable to me but of course, I could be wrong, in which case I am sure you can give your view politely. Thanks.

[superg1] 03/2/2021 15:24

2tyke

Wa that on another website re FUM and the explanation of logic when it comes to investing, logic is formed by the masses thus being logical is a losing method.

[inanaco] 03/2/2021 15:10

sorry was caught up in something else so i quickly posted the value .... just thought you missed a good post there for the LSE

the fact that GSK will front 75m for a candidate not even selected gives an indicator of value

[torquayfan] 03/2/2021 15:08

Inan 36509 - the thread was about the progress of other 2nd Gen vaccines - not about what their value might be. If you want to use the link for your own purposes - feel free. That's what it's there for.

[gazza] 03/2/2021 14:44

Inan,
" caught up"
or overtaken? lol

[inanaco] 03/2/2021 14:35

wonder if that value will cause confusion for Gazza ....its more than the current Mcap

[inanaco] 03/2/2021 14:33

Tf your link........ why don't you read them and highlight

""" GSK will be the marketing authorisation holder for the next generation vaccine, except in Switzerland, and will have exclusive rights to develop, manufacture, and market the next generation COVID-19 vaccine in all countries with the exception of Germany, Austria and Switzerland.

GSK will make an upfront payment of €75m and a further payment of €75m, conditional on the achievement of certain goals.""""



after all that sec gen vaccine then is valued probably at Euro 150m clinical

[gazza] 03/2/2021 13:25

Empty, Hopefully the commercial machine of Scancell has been fully mobilised is banging at the door of number 10.